Legrand E, Hedde C, Gallois Y, Degasne I, Boux de Casson F, Mathieu E, Baslé M F, Chappard D, Audran M
Service de Rhumatologie, Centre Hospitalier Universitaire, Angers, France.
Bone. 2001 Jul;29(1):90-5. doi: 10.1016/s8756-3282(01)00478-1.
The exact mechanism of bone loss remains unknown in primary male osteoporosis. It has been suggested that estrogen and sex hormone binding globulin (SHBG) play a role in regulating bone turnover and bone mass in healthy men > 65 years of age. In the present study, 80 men (mean age 49.7 years) with bone mineral density >2.5 SD below the young adult value and 40 age-matched controls were recruited to evaluate the relationships between sex hormone levels, bone biochemical markers levels, and bone mineral density. Fasting serum samples were assayed for total and free testosterone total estradiol, and SHBG. The free androgen index, was calculated as: [total testosterone/SHBG * 100]. Bone remodeling was evaluated by measurement of urinary levels of the C-telopeptide of type I collagen (CTx) and free deoxypyridinoline (D-Pyr), serum osteocalcin, and bone-specific alkaline phosphatase (bSAP). There was no significant difference between controls and osteoporotic men according to age, body mass index (BMI), total testosterone, and estradiol. In contrast, serum SHBG level was significantly higher (+42.2%), whereas free androgen index was lower (-24.8%) in patients with primary or secondary osteoporosis. Testosterone and estradiol levels did not correlate with any bone resorption or bone formation markers. In contrast, stepwise linear regression analysis showed that SHBG was significantly correlated with D-Pyr (r = 0.45, p < 0.05) and CTx (r = 0.34, p < 0.05) in primary osteoporosis. In secondary osteoporosis, SHBG was correlated with D-Pyr (r = 0.48, p < 0.05) and bSAP (r = 0.55, p < 0.01). After adjustment for age and BMI, hip bone mineral density (BMD) was not associated with testosterone or estradiol but only with serum SHBG (r = -0.33, p < 0.01) in primary osteoporosis. The same relationship was observed in men with secondary osteoporosis (r = -0.34, p < 0.01). Among osteoporotic patients, spinal radiography showed at least one vertebral crush fracture in 36 men and none in 44. Serum SHBG concentration was significantly associated with the presence of vertebral fracture: the odds ratio was 2.0 (95% confidence interval [CI] 1.2-3.5) for an increase of one standard deviation of SHBG. In conclusion, the present study showed that serum SHBG concentration is increased in middle-aged men with primary or secondary osteoporosis and is correlated with bone remodeling markers, hip bone mineral density, and vertebral fracture risk.
男性原发性骨质疏松症中骨质流失的确切机制尚不清楚。有研究表明,雌激素和性激素结合球蛋白(SHBG)在调节65岁以上健康男性的骨转换和骨量方面发挥作用。在本研究中,招募了80名骨矿物质密度比年轻成人平均值低2.5个标准差以上的男性(平均年龄49.7岁)和40名年龄匹配的对照者,以评估性激素水平、骨生化标志物水平和骨矿物质密度之间的关系。采集空腹血清样本,检测总睾酮、游离睾酮、总雌二醇和SHBG。游离雄激素指数的计算方法为:[总睾酮/SHBG×100]。通过测量尿I型胶原C端肽(CTx)和游离脱氧吡啶啉(D-Pyr)水平、血清骨钙素和骨特异性碱性磷酸酶(bSAP)来评估骨重塑。根据年龄、体重指数(BMI)、总睾酮和雌二醇水平,对照组和骨质疏松男性之间没有显著差异。相比之下,原发性或继发性骨质疏松症患者的血清SHBG水平显著升高(+42.2%),而游离雄激素指数较低(-24.8%)。睾酮和雌二醇水平与任何骨吸收或骨形成标志物均无相关性。相比之下,逐步线性回归分析显示,在原发性骨质疏松症中,SHBG与D-Pyr(r = 0.45,p < 0.05)和CTx(r = 0.34,p < 0.